Tumor DNA study aims to unlock secrets of drug resistance

NCT ID NCT03347318

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affect drug response. This is an observational study, meaning no new treatment is being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand why some tumors stop responding to targeted drugs, potentially guiding future treatment choices.
What could go wrong
This is an observational study, not a treatment trial. It will not directly benefit participants, and the findings may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • A.O. Città della Salute e della Scienza di Torino - Presidio ospedaliero Ostetrico Ginecologico Sant'Anna

    Turin, Italy

  • AOU Città della Salute e della Scienza di Torino - Presidio Molinette

    Turin, Italy

  • AOU S. Luigi Gonzaga

    Orbassano, Italy

  • Azienda Ospedaliera Niguarda Ca'Granda

    Milan, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

  • Azienda Ospedaliero-Universitaria Careggi

    Genova, Italy

  • Fondazione IRCCS - Istituto Nazionale dei Tumori

    Milan, Italy

  • IEO - Istiuto Europeo di Oncologia

    Milan, Italy

  • IOV - Istituto Oncologico Veneto

    Padova, Italy

  • Istituto Di Candiolo - Fondazione Del Piemonte Per L'Oncologia (FPO-Irccs)

    Candiolo, Italy

  • Ospedale Mauriziano Umberto I

    Turin, Italy

  • Ospedale Regionale Umberto Parini

    Aosta, Italy

  • Policlinico S.Orsola Malpighi

    Bologna, Italy

  • Policlinico Universitario Campus Biomedico

    Roma, Italy

  • Presidio Ospedaliero Martini

    Turin, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.